Jan Hammarsten

2.0k total citations
34 papers, 1.5k citations indexed

About

Jan Hammarsten is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Urology. According to data from OpenAlex, Jan Hammarsten has authored 34 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 12 papers in Surgery and 11 papers in Urology. Recurrent topics in Jan Hammarsten's work include Prostate Cancer Diagnosis and Treatment (11 papers), Urinary Bladder and Prostate Research (11 papers) and Peripheral Artery Disease Management (9 papers). Jan Hammarsten is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (11 papers), Urinary Bladder and Prostate Research (11 papers) and Peripheral Artery Disease Management (9 papers). Jan Hammarsten collaborates with scholars based in Sweden and United States. Jan Hammarsten's co-authors include Benkt Högstedt, Dan Mellström, Ralph Peeker, Jan Holm, T. Scherstén, Ann‐Christin Bylund, Jan‐Erik Damber, Claes–Göran Cederlund, M Krotkiewski and Ann‐Christin Bylund‐Fellenius and has published in prestigious journals such as Cancer, The Journal of Urology and International Journal of Cancer.

In The Last Decade

Jan Hammarsten

33 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Hammarsten Sweden 16 622 616 516 319 256 34 1.5k
‬Ahmed M. Harraz Egypt 18 300 0.5× 388 0.6× 116 0.2× 430 1.3× 119 0.5× 91 1.1k
Christopher Nardo United States 10 148 0.2× 755 1.2× 148 0.3× 398 1.2× 84 0.3× 19 1.7k
Barbara Rantner Germany 20 1.7k 2.7× 65 0.1× 117 0.2× 723 2.3× 120 0.5× 72 2.2k
Vaughan Ed United States 15 310 0.5× 115 0.2× 100 0.2× 365 1.1× 75 0.3× 30 912
Ognen Ivanovski North Macedonia 15 132 0.2× 72 0.1× 81 0.2× 259 0.8× 103 0.4× 39 988
Marco Dellabella Italy 15 886 1.4× 639 1.0× 48 0.1× 145 0.5× 46 0.2× 49 1.2k
W. Dietrich Germany 20 70 0.1× 44 0.1× 119 0.2× 730 2.3× 274 1.1× 68 1.6k
Jerome F. O’Hara United States 21 223 0.4× 45 0.1× 196 0.4× 787 2.5× 109 0.4× 56 1.2k
Erik Spaepen United States 13 88 0.1× 42 0.1× 139 0.3× 315 1.0× 110 0.4× 56 981
E. R. Yendt Canada 20 598 1.0× 33 0.1× 154 0.3× 169 0.5× 226 0.9× 45 1.3k

Countries citing papers authored by Jan Hammarsten

Since Specialization
Citations

This map shows the geographic impact of Jan Hammarsten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Hammarsten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Hammarsten more than expected).

Fields of papers citing papers by Jan Hammarsten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Hammarsten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Hammarsten. The network helps show where Jan Hammarsten may publish in the future.

Co-authorship network of co-authors of Jan Hammarsten

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Hammarsten. A scholar is included among the top collaborators of Jan Hammarsten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Hammarsten. Jan Hammarsten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hammarsten, Jan, et al.. (2020). Men with type 2 diabetes mellitus have a lower detection rate of prostate cancer. International Journal of Urology. 27(9). 817–820. 1 indexed citations
2.
Hammarsten, Jan, et al.. (2018). A stage-dependent link between metabolic syndrome components and incident prostate cancer. Nature Reviews Urology. 15(5). 321–333. 27 indexed citations
3.
Mellström, Dan, Ralph Peeker, Jan Hammarsten, et al.. (2014). Lower urinary tract symptoms are associated with low levels of serum serotonin, high levels of adiponectin and fasting glucose, and benign prostatic enlargement. Scandinavian Journal of Urology. 49(2). 155–161. 10 indexed citations
4.
Hammarsten, Jan & Ralph Peeker. (2011). Urological aspects of the metabolic syndrome. Nature Reviews Urology. 8(9). 483–494. 79 indexed citations
5.
Hammarsten, Jan, Jan‐Erik Damber, Ralph Peeker, Dan Mellström, & Benkt Högstedt. (2010). A higher prediagnostic insulin level is a prospective risk factor for incident prostate cancer. Cancer Epidemiology. 34(5). 574–579. 40 indexed citations
6.
Hammarsten, Jan, J‐E. Damber, Magnus K. Karlsson, et al.. (2008). Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases. 12(2). 160–165. 72 indexed citations
7.
Hammarsten, Jan. (2006). Benign Prostatic Hyperplasia and Clinical Prostate Cancer - Two New Components of the Metabolic Syndrome. Current Hypertension Reviews. 2(4). 301–309. 2 indexed citations
8.
Hammarsten, Jan & Benkt Högstedt. (2005). Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. European Journal of Cancer. 41(18). 2887–2895. 173 indexed citations
9.
Hammarsten, Jan & Benkt Högstedt. (2004). Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high‐stage and high‐grade clinical prostate cancer. Blood Pressure. 13(1). 47–55. 112 indexed citations
10.
Hammarsten, Jan, et al.. (2001). Hyperinsulinaemia as a Risk Factor for Developing Benign Prostatic Hyperplasia. European Urology. 39(2). 151–158. 251 indexed citations
11.
Hammarsten, Jan, et al.. (1998). Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases. 1(3). 157–162. 247 indexed citations
12.
Åström, Lennart, ANNA WEIMARCK, Frank Aldenborg, et al.. (1998). S-phase fraction related to prognosis in localised prostate cancer. No specific significance of chromosome 7 gain or deletion of 7q31.1. International Journal of Cancer. 79(6). 553–559. 8 indexed citations
13.
Hammarsten, Jan. (1997). [Saphenous vein-saving surgery--an alternative to stripping].. PubMed. 112(10). 361–4. 1 indexed citations
14.
Hammarsten, Jan, et al.. (1996). A Study of the Mechanisms by Which Haemodynamic Function Improves following Long Saphenous Vein-Saving Surgery. Phlebology The Journal of Venous Disease. 11(3). 102–105. 8 indexed citations
15.
16.
Jivegård, Lennart, Jakob Holm, David Bergqvist, et al.. (1991). Acute lower limb ischemia: failure of anticoagulant treatment to improve one-month results of arterial thromboembolectomy. A prospective randomized multi-center study.. PubMed. 109(5). 610–6. 11 indexed citations
17.
Hammarsten, Jan, et al.. (1990). Long saphenous vein saving surgery for varicose veins. A long-term follow-up. European Journal of Vascular Surgery. 4(4). 361–364. 68 indexed citations
18.
Hammarsten, Jan, et al.. (1989). Urethral Strictures following Transurethral Resection of the Prostate. The Role of the Catheter. British Journal of Urology. 63(4). 397–400. 43 indexed citations
19.
Hammarsten, Jan, et al.. (1989). Arterial embolism and atrial arrhythmias. European Journal of Vascular Surgery. 3(3). 261–266. 4 indexed citations
20.
Ekroth, Rolf, Per Björntorp, Jan Hammarsten, et al.. (1982). Effect of Valvular Aortic Stenosis on Insulin Sensitivity. Scandinavian Journal of Thoracic and Cardiovascular Surgery. 16(2). 141–144. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by ‬Ahmed M. Harraz Breakdown of academic impact, for papers by Christopher Nardo Breakdown of academic impact, for papers by Barbara Rantner Breakdown of academic impact, for papers by Vaughan Ed Breakdown of academic impact, for papers by Ognen Ivanovski Breakdown of academic impact, for papers by Marco Dellabella Breakdown of academic impact, for papers by W. Dietrich Breakdown of academic impact, for papers by Jerome F. O’Hara Breakdown of academic impact, for papers by Erik Spaepen Breakdown of academic impact, for papers by E. R. Yendt
Rankless by CCL
2026